questions , page-4

  1. 1,546 Posts.
    lightbulb Created with Sketch. 5
    It's not just marketing, Luramist has yet to go through Phase 3 trials. I'm not sure how much that's likely to cost, but with the $50 million they've got Acrux can probably afford to run these itself.

    I'd be a bit happier if they partner more products, however, preferably with new partners. At the moment they only have KV (selling Evamist) and Eli Lilly (Axiron and animal health products), having lost Organon and now Vivus.

    Now Axiron is out of their hands, I'd like to see Acrux get the rest of the pipeline moving.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.6¢
Change
0.000(0.00%)
Mkt cap ! $6.524M
Open High Low Value Volume
1.5¢ 1.6¢ 1.5¢ $9.887K 624.5K

Buyers (Bids)

No. Vol. Price($)
1 6355 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 20000 1
View Market Depth
Last trade - 15.00pm 26/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.